ibi343
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Locally Advanced Unresectable or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ibi133 Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/2 | CCC |
ibi354 Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/2 | CCC |
Irinotecan Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Eloxatin Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
Calcium folinate pentahydrate Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
FLUOROURACILUM Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | CC |
sg1906 Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
ibi343 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →